Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

GF Trap-Eye for the treatment of wet AMD, diabetic eye diseases, and other eye diseases and disorders. Bayer HealthCare AG and Regeneron will jointly commercialize the VEGF Trap-Eye outside the United States, and Regeneron maintains exclusive rights in the United States.

In the Phase 2 wet AMD trial, data were presented from a pre-planned interim analysis of the first 78 patients who completed 12 weeks of the study. The randomized, multi-center trial involves 150 patients who were randomized to 5 groups and treated with the VEGF Trap-Eye in one eye. Two groups received either 0.5 or 2.0 milligrams (mg) of VEGF Trap-Eye administered every 4 weeks, and three groups received a single dose of 0.5, 2.0, or 4.0 mg of VEGF Trap-Eye. Patients were monitored for safety, retinal thickness, and visual acuity over 12 weeks. The VEGF Trap-Eye met its primary endpoint of a statistically significant reduction in retinal thickness after 12 weeks compared with baseline (all groups combined, decrease of 135 microns, p less than 0.0001). Mean change in visual acuity, a key secondary endpoint of the study, also demonstrated a statistically significant improvement (all groups combined, increase of 5.9 letters, p less than 0.0001). There were no drug-related serious adverse events, and treatment with the VEGF Trap-Eye was generally well-tolerated. The most common adverse events were those typically associated with intravitreal injections. Interim data for all dose groups were presented at the ARVO meeting. The Phase 2 wet AMD study is now fully enrolled and results for all patients will be presented at a future scientific meeting.

Encouraging results were also presented from a Phase 1 study of VEGF Trap-Eye in DME. In this open-label safety study, the VEGF Trap-Eye was administered as a single 4.0 mg intravitreal injection to 5 patients with longstanding diabetes and multiple prior treatments for DME. The single injection resulted in a marked decrease in mean central retina
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:7/30/2015)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on ... financial results and provide a corporate update. Arena will ... Market closes that day. The conference call ... and 914.495.8552 for international callers. Please specify to the ...
(Date:7/30/2015)... Mass., July 30, 2015   HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced total revenue of $73.6 million ... to $70.1 million for the quarter ended June ... approximately $6.0 million, or nine percentage points, during ...
(Date:7/29/2015)... , July 30, ... Guidance   ... including Core Earnings and ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5
... VILLAGE, Calif., Dec. 21 Specialists On Call, ... 10,000th emergency teleneurology consultation since the company,s inception. ... SOC,s leadership position as the largest private emergency teleneurology ... when it recently responded to a neurologic emergency at ...
... , LJUBLJANA, Slovenia, Dec. 21 Slovenian Minister of ... Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery ... platform from Varian Medical Systems (NYSE: VAR ... the country,s only radiotherapy department access to advanced radiotherapy ...
Cached Medicine Technology:Specialists On Call Delivers 10,000th Emergency Teleneurology Consultation 2Specialists On Call Delivers 10,000th Emergency Teleneurology Consultation 3Slovenia's Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB 2Slovenia's Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB 3Slovenia's Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... Nursing Center,” to announce its position as one of Medicare’s top-rated care ... staff members support the CMS rating system, which monitors health inspections, staffing, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New Way ... Training Capability , World renown body weight trainer, Paul Ziachik, announces today ... dramatically increases a person’s training capability. , The American College of Sports Medicine ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... smiles, including lip lowering, gum contouring and surgery, as well as the patented gum ... artistry that has made him popular with many patients from around the world. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
Breaking Medicine News(10 mins):Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... to avoid devastating vision injuries, group says , , ... in the United States, about 40,000 people suffer ... Ophthalmology (AAO), which recommends that all athletes wear ... eye-care professional. , Lenses made from polycarbonate materials ...
... may provide protection against heart disease ... and certain cancers, ARLINGTON, ... the recognized ranks of healthful whole grains, according,to an announcement this week ... food labels to bear the whole grain health,claim. This will enable consumers ...
... International,Rescue Committee emergency team members have arrived in ... deployment to the region as the IRC,prepares for ... "Nearly all homes were destroyed in the ... no access to clean drinking water," says the,IRC,s ...
... Facility, CARSON, Calif., May 9 Leiner ... that it has submitted a,proposed agreement with the ... Court in Delaware for approval. The proposed agreement ... and distribution of certain over-the-counter (OTC) drug products ...
... for Iraq and Afghanistan Veterans Gather in Virginia to,Envision ... CHANTILLY, Va., May 9 As the war ... toll climbs above 4,000 and,casualty numbers approach the 30,000 ... on the homefront have organized to help,bereaved families and ...
... of stimulants a fixture of European nightlife, study says , , ... adults in Europe are drinking alcohol and taking drugs for ... people who are regular nightlife-goers. , The results showed ... aged 16 to 35 drink alcohol to increase their chances ...
Cached Medicine News:Health News:Protective Eyewear Key to Sports Safety 2Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2Health News:Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Young Adults Using Alcohol, Drugs for Better Sex 2
... Eliminate the need for makeshift, modified ... Why waste time gathering parts when your ... need to deliver the utmost in Heliox ... therapy is fast becoming the standard of ...
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... nebulizer utilizing Vibrating Mesh Technology to ... suffering from Asthma, COPD or other ... product size and handy carrying case ... takes them. Powerful delivery comparable to ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
Medicine Products: